QiagenAt the beginning of September, Jonathan M. Pratt succeeded Thierry Bernard as CEO of Qiagen N.V. Bernard had led the biotech pioneer for nearly seven years.
Lonza GroupSamanta Cimitan will join Lonza as Chief Commercial Officer (CCO), Senior Vice President and a member of the Extended Executive Committee on 1 January 2027. In the newly created role, she will lead Strategic Enterprise Account Management, Global Marketing and Commercial Excellence. She´s been with Lonza before her CEO role at Celonic for the last three years.
EpilepsyGTXLondon-based EpilepsyGTx has appointed Dr Teresa Nunes as Chief Medical Officer (CMO) to support the continued development of the company’s gene therapy program, including its progression toward clinical development.
Simris Group ABProfessor Andreas Pahl took over as Chief Executive Officer of Simris Biologics GmbH in mid-July. The subsidiary of Swedish Simris Group based in Berlin, develops next-generation antibody-drug conjugate (ADC) payloads based on nature-derived technologies.
ArdenaAriane de Ganck, PhD, took over the position as new Chief Scientific Officer (CSO) at Ardena. She started in 2019 at the Ghent-based CDMO/CRO.
PeptiSystems ABSwedish life science company PeptiSystems has appointed Ida Nordberg as Chief Financial Officer (CFO). The appointment marks another milestone in the company’s development and further strengthens the organization as it enters its next phase of commercialization and international expansion
SymeresWith the appointment of Russell Thomas as Chief Scientific Officer, Symeres and Axxam are further strengthening their strategic collaboration. The goal is to provide pharmaceutical and biotechnology companies with an integrated platform for drug discovery and development from a single source.
Exonate, Ltd.By appointing Olav Hellebø as Chief Executive Officer, biotechnology company Exonate Ltd. aims to accelerate the clinical development of its lead candidate for diabetic eye disease.
Rezon BioDr Ralf Otto, a former manager at Boehringer Ingelheim and Rentschler, has been appointed as the new Chief Operating Officer of the Polish company Rezon Bio.
Immunic AGErik Lundgren assumed his role as the new CEO of Immunic. He succeeds Dr Daniel Vitt, who will continue to oversee the biotech company’s scientific strategy.